Steven Prestrelski Xeris Biopharma Holdings, Inc. (XERS) insider trading activity

Steven Prestrelski is Chief Scientific Officer of Xeris Biopharma Holdings, Inc.. Currently has a direct ownership of 719,780 shares of XERS, which is worth approximately $2.43 Million. The most recent transaction as insider was on Jan 31, 2023, when has been sold 150,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 720K

0% 3M change

0% 12M change

Total Value Held $2.43 Million

STEVEN PRESTRELSKI Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 31 2023	BUY Grant, award, or other acquisition	-	150,000 Added 17.25%	719,780 Common Stock
Feb 22 2022	SELL Open market or private sale	$27,172 $2.42 p/Share	11,228 Reduced 1.93%	569,780 Common Stock
Feb 22 2022	BUY Exercise of conversion of derivative security	$7,747 $0.69 p/Share	11,228 Added 1.9%	581,008 Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	75,000 Added 11.63%	569,780 Common Stock
Oct 05 2021	BUY Grant, award, or other acquisition	-	494,780 Added 50.0%	494,780 Common Stock

Also insider at

XERS

XERIS PHARMACEUTICALS INC Healthcare

Chief Scientific Officer